Dishman Carbogen Amcis Ltd. · NSE:DCAL
Dishman Carbogen Amcis — Q4 FY2023 Earnings Presentation
30 slides from Dishman Carbogen Amcis's earnings presentation, May 23, 2023
Slide 1: Cover letter to stock exchanges
23rd May, 2023 To, To, Department of Corporate Services The Manager, BSE Ltd. Listing Department, Phiroze Jeejeebhoy Towers, National Stock Exchange of India Ltd. Dalal Street, “Exchange Plaza”, C-1, Block G, Mumbai – 400 001. Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051. Ref.: Scrip Code No.
Slide 2: Investor Presentation Quarter ended March 31st, 2023
Investor Presentation Quarter ended March 31 st , 2023
Slide 3: Safe Harbor Statement
SAFE HARBOR STATEMENT This presentation and the following discussion may contain “forward looking statements” by Dishman Carbogen Amcis Limited (‘Dishman’ or the ‘Company’) that are not historical in nature. These forward- looking statements, which may include statements relating to future results o
Slide 4: Dishman in a Nutshell
DISHMAN IN A NUTSHELL 4 decades 2,200+ Team Strength 25 28 Committed Members Embracing of Long-Standing Track Record in our Culture of Innovation & Sustainability CRAMS Dedicated Team/Scientist Working Multi-Purpose MANUFACTURING RESEARCH & DEVELOPMENT APIS in R&D - 950+ FACILITIES Globally and HIPO
Slide 5: Past Performance at a Glance
PAST PERFORMANCE AT A GLANCE Revenue from Operations (₹ mn) EBITDA and EBITDA % Cash Profit (₹ mn) EBITDA EBITDA % 4,499 24,129 4,087 21,407 5,519 20,586 20,436 19,120 4,976 3,374 3,260 3,902 4,142 2,538 2,744 26.8% 24.3% 18.2% 17.2% 14.3% FY19 FY20 FY21 FY22 FY23 FY19 FY20 FY21 FY22^ FY23^ FY19 FY2
Slide 6: Agenda
AGENDA 01 Quarter Highlights 02 Company Overview 03 Industry Overview
Slide 7: Quarter Highlights
QUARTER Dishman Carbogen Ar
Slide 8: Q4 FY23 Result Highlights
Q4 FY23 RESULT HIGHLIGHTS NET REVENUE (₹ mn) EBITDA (₹ mn) & EBITDA MARGIN 6,186 5,690 773 830 13.6% 13.4% Q4FY22 Q4FY23 Q4FY22^ Q4FY23^ CASH PAT (₹ mn) & CASH EPS (₹) 4.2 4.2 651 651 Q4FY22^@ Q4FY23^ Cash PAT = Adjusted PAT + (Depreciation - additional goodwill amortization), @ adjusted for merger
Slide 9: FY23 Result Highlights
FY23 RESULT HIGHLIGHTS NET REVENUE (₹ mn) EBITDA (₹ mn) & EBITDA MARGIN 24,129 4,142 21,407 3,902 18.2% 17.2% FY22 FY23 FY22^ FY23^ CASH PAT (₹ mn) & CASH EPS (₹ ) 3,374 3,260 21.5 20.8 FY22^@ FY23^ Cash PAT = Adjusted PAT + (Depreciation - additional goodwill amortization) @ adjusted for merger imp
Slide 10: Consolidated P&L Statement
CONSOLIDATED P&L STATEMENT Particulars (₹ mn) Q4 FY23 Q4 FY22 YoY % FY23 FY22 YoY% Income from Operations (Net) 6,185.6 5,689.9 8.7% 24,129.2 21,406.9 12.7% COGS 1,794.0 1,477.2 21.4% 5,114.1 4,474.2 14.3% Employee Expenses 2,553.3 2,525.9 1.1% 10,352.7 9,814.9 5.5% Other Expenses 1,323.9 1,466.8 -9
Slide 11: Consolidated Balance Sheet
CONSOLIDATED BALANCE SHEET Particulars (₹ mn) Mar-23 Mar-22 Particulars (₹ mn) Mar-23 Mar-22 Equity Share Capital 313.6 313.6 Property, plant and equipment 19,609.3 17,429.5 Capital Work in Progress 9,962.7 7,548.2 Other Equity 57,783.1 55,175.8 Right to use Lease Assets 2,699.2 2,891.1 Total - Shar
Slide 12: Revenue Breakup Analysis
REVENUE BREAKUP ANALYSIS Revenues (₹ mn) Q4 FY23 Q4 FY22 YoY % FY23 FY22 YoY% CARBOGEN AMCIS - Contract Research & 4,363.1 3,999.6 9.1% 17,005.6 14,896.6 14.2% Manufacturing Services1 CARBOGEN AMCIS- Cholesterol & Vit D 599.0 632.2 -5.3% 2,701.9 3,061.5 -11.7% Analogues2 DCAL India - NCE APIs & Inte
Slide 13: Revenue Break-up
REVENUE BREAK-UP Total Operating Revenue – Q4 FY23 Total Operating Revenue – FY23 DCAL India - NCE APIs & Intermediates 10.1% 9.7% 11.2% 11.8% DCAL India - Quats & Generics 8.2% 7.9% CARBOGEN AMCIS - Contract Research & Manufacturing 70.5% Services 70.5% CARBOGEN AMCIS - Cholesterol & Vit D Analogue
Slide 14: Margin Analysis
MARGIN ANALYSIS EBITDA Margin %* Q4 FY23 Q4 FY22 FY23 FY22 CARBOGEN AMCIS - Contract Research & 16.1% 17.3% 20.3%@ 19.7% Manufacturing Services1 # CARBOGEN AMCIS - Cholesterol & Vit D Analogues2 13.2% 19.2% 17.0% 28.1% DCAL India - NCE APIs & Intermediates3 1.9% - 3.0% - DCAL India - Quats & Generic
Slide 15: Q4 & Full Year FY23 Result Highlights
Q4 & Full Year FY23 RESULT HIGHLIGHTS Net Revenue at Rs 6,185.6 mn in Q4 FY23 up by 8.7% YoY due to increase in CRAMS revenue from India and Switzerland. DCAL India – NCE APIs and Intermediates revenue increased by 51.2% in Q4 FY23 and 53.3% YOY primarily due to increasing supplies of CRAMS commerci
Slide 16: Impairment of Fixed Assets
Impairment of Fixed Assets The constant growth of Carbogen Amcis (“CGAM”) Group led CGAMCH decided to invest in the new production facility in Hunzenschwil in 2021 as a part of further expansion to cater the future demand. The project is expected to generate a future economic benefit for the group.
Slide 17: Operational Improvement Q4 FY23 – Naroda Unit I
OPERATIONAL IMPROVEMENT Q4 FY23 – NARODA UNIT - I Ongoing Civil jobs for installation of the 2 new ANFDs. The 2 x 5 KL ANFD are supposed to be delivered within the next 2-3 weeks. Addition will significantly increase the productivity of Naroda U1.The two ANFD are supposed to be operational by mid se
Slide 18: Operational Improvement Q4 FY23 – Naroda Unit II
OPERATIONAL IMPROVEMENT Q4 FY23 – NARODA UNIT - II Private bonded warehouse area was increased using a part which historically was used for U1. Now the private bonded warehouse is well equipped to properly store all the materials used for U2. Powder processing area Line 1 was completed introducing R
Slide 19: Operational Improvement Q4 FY23 – Bavla
OPERATIONAL IMPROVEMENT Q4 FY23 – BAVLA New QC lab from GD-Waldner was fully qualified and it is now operational. In the past few months, several equipment were shifted into the new lab. Currently the QC facilities size has doubled and capable to sustain the future site expansions. The new stability
Slide 20: Company Overview
COMPANY Dishman Carbogen Ar
Slide 21: About Us
ABOUT US Established in 1983, Dishman Carbogen Amcis Limited is a fully integrated CRAMS (Contract Research & Manufacturing) company with strong capabilities right from process research & development to late stage clinical and commercial manufacturing and supply of API to innovator pharmaceutical co
Slide 22: Key Strengths
KEY STRENGTHS Preferred global outsourcing Upfront investment of more partner with capabilities across the than ₹10,000 mn in large entire CRAMS value chain scale multi-purpose manufacturing capacities Strong chemistry skills The HIPO facility at Bavla, India is the largest HIPO facility in Asia. Di
Slide 23: Manufacturing Facilities
ROBUST R&D CAPABILITIES Facilities are approved by recognised health agencies: Superior Chemistry Skills & Capabilities USFDA, MEB, SWISS MEDIC, ANSM, WHO, MFDS, PMDA 28 dedicated R&D labs with multiple shift R&D CARBOGEN AMCIS BV., Veenendaal, The CARBOGEN AMCIS operations, including HIPO labs (Sha
Slide 24: Preferred Global Outsourcing Partner
PREFERRED GLOBAL OUTSOURCING PARTNER CLOSE PROXIMITY LARGE SCALE INTEGRATED ACROSS THE STRONG CHEMISTRY TO CLIENTS WITH MANUFACTURING VALUE CHAIN CAPABILITIES GLOBAL PRESENCE CAPACITIES Integrated CRAMS Player present along the entire value chain from building blocks to commercialization and product
Slide 25: Integrated CRAMS Player
INTEGRATED CRAMS PLAYER CARBOGEN AM CIS (CA) STRON G RESEARCH CAPABILITIES § Focus is on supporting the development process from bench to market § Process research and development to the supply of APIs for preclinical studies, clinical trials and commercial use DISHM AN IN DIA STRON G M AN UFACTURIN
Slide 26: Cutting Edge HIPO Capabilities
CUTTING EDGE HIPO CAPABILITIES The HIPO facility at Bavla, India, is one of the kind facility in the world and the largest facility in Asia. The facility has a sound mix of Kilo lab and full- scale manufacturing units to cater to both small volume and large volume orders. State of the art containmen
Slide 27: Industry Overview
INDUSTRY Dishman Carbogen Ar
Slide 28: Expected Global Spending by Therapy Areas in 2027
EXPECTED GLOBAL SPENDING BY THERAPY AREAS IN 2027 Oncology & Obesity expected to lead growth 5-Yr CAGR 2023-2027 Oncology 377 13-16% Immunology 177 3-6% Diabetes 168 3-6% Top 20 Therapy Areas (US$ bn) - 2027 Cardiovascular 126 1-4% Respiratory 92 3-6% CNS 81 2-5% Infectious diseases 74 2-5% GU sexua
Slide 29: Specialty: Market Share & Growth
SPECIALTY: MARKET SHARE & GROWTH Specialty medicines will represent about 43% of global spending in 2027 and 56% of total spending in developed markets 56% 49% 47% 43% 43% 40% 39% 36% 32% 27% 28% 24% 16% 16% 12% 10% 2012 2017 2022 2027 Pharmerging Other Developed Global 10 Developed Source: IQVIA In
Slide 30: For Further Queries
FOR FURTHER QUERIES Mr. Harshil Dalal Dishman Carbogen Amcis Ltd Global CFO Dishman Corporate House Email: harshil.dalal@dishmangroup.com Iscon-Bopal Road, Ambli Ahmedabad - 380058 Gujarat, Mr. Binay Sarda India Ernst & Young LLP www.imdcal.com P: +91 9920893764 Email: binay.sarda@in.ey.com
Dishman Carbogen Amcis — Q4 FY2023 Earnings Presentation on 6ix